logo
Plus   Neg
Share
Email

Merck Announces Label Expansion For KEYTRUDA In Canada - Quick Facts

Merck (MRK) announced that Health Canada has expanded the label for KEYTRUDA (pembrolizumab), the company's anti-PD-1 therapy, to include approval for the treatment of metastatic non-squamous non-small cell lung cancer or NSCLC, in combination with pemetrexed and platinum chemotherapy, in adults with no EGFR or ALK genomic tumour aberrations, and no prior systemic chemotherapy treatment for metastatic NSCLC.

KEYTRUDA was first approved in Canada in 2015 and currently has eight indications in a number of disease areas, including non-small cell lung cancer, classical Hodgkin lymphoma, melanoma and bladder cancer.

For comments and feedback contact: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Luckin Coffee Inc., Starbucks Corp.'s biggest rival in China, filed for an Initial Public Offering in the U.S. In a filing with the Securities and Exchange Commission, the China-based coffee chain said it has applied for listing its American Depositary Shares or ADSs on the Nasdaq under the symbol "LK" and also set a placeholder amount of $100 million. Micro-blogging site Twitter Inc. (TWTR) Tuesday reported a surge in its first-quarter profit. Both earnings and revenues beat analysts' estimates, sending shares up by 6 percent in the pre-market trading. But, Twitter's average monthly active users or MAU figure declined from last year. Verizon Communications Inc. on Tuesday reported a nearly 11 percent increase in profit for the first quarter from last year on higher wireless revenues and flat expenses. Adjusted earnings per share for the quarter beat analysts' estimates, while revenues were in-line with expectations. Looking ahead, the company raised its adjusted earnings outlook for fiscal 2019.
Follow RTT